Khan, I;
Morris, S;
Hackshaw, A;
Lee, SM;
(2015)
Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy.
BMJ Open
, 5
(7)
, Article e006733. 10.1136/bmjopen-2014-006733.
Preview |
Text
Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy..pdf Download (1MB) | Preview |
Abstract
To assess the cost-effectiveness of erlotinib versus supportive care (placebo) overall and within a predefined rash subgroup in elderly patients with advanced non-small-cell lung cancer who are unfit for chemotherapy and receive only active supportive care due to their poor performance status or presence of comorbidities.
Archive Staff Only
 |
View Item |
